Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SAIRAH AHMED and LORETTA NASTOUPIL.
SAIRAH AHMED
Connection Strength
2.681
LORETTA NASTOUPIL
  1. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol. 2024 01; 204(1):e11-e16.
    View in: PubMed
    Score: 0.241
  2. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.
    View in: PubMed
    Score: 0.223
  3. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
    View in: PubMed
    Score: 0.207
  4. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5.
    View in: PubMed
    Score: 0.201
  5. Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma. Blood Adv. 2024 Mar 23.
    View in: PubMed
    Score: 0.062
  6. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2024 Jan 22; 1-5.
    View in: PubMed
    Score: 0.061
  7. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica. 2023 Nov 30.
    View in: PubMed
    Score: 0.061
  8. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 2023 11 14; 7(21):6785-6789.
    View in: PubMed
    Score: 0.061
  9. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 11 09; 16(1):111.
    View in: PubMed
    Score: 0.061
  10. A single-cell atlas of CD19 chimeric antigen receptor T?cells. Cancer Cell. 2023 11 13; 41(11):1835-1837.
    View in: PubMed
    Score: 0.060
  11. Prolonged cytopenia following CD19 CAR T?cell therapy is linked with bone marrow infiltration of clonally expanded IFN?-expressing CD8 T?cells. Cell Rep Med. 2023 08 15; 4(8):101158.
    View in: PubMed
    Score: 0.060
  12. Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br J Haematol. 2023 07; 202(2):248-255.
    View in: PubMed
    Score: 0.058
  13. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica. 2023 04 01; 108(4):1163-1167.
    View in: PubMed
    Score: 0.058
  14. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 04; 29(4):906-916.
    View in: PubMed
    Score: 0.058
  15. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med. 2022 11 15; 3(11):100720.
    View in: PubMed
    Score: 0.057
  16. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia. 2022 Nov; 36(11):2669-2677.
    View in: PubMed
    Score: 0.056
  17. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.
    View in: PubMed
    Score: 0.056
  18. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discov. 2022 09 06; 3(5):428-443.
    View in: PubMed
    Score: 0.056
  19. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2023 02 01; 41(4):745-755.
    View in: PubMed
    Score: 0.056
  20. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood. 2022 08 04; 140(5):504-515.
    View in: PubMed
    Score: 0.056
  21. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022 07 01; 107(7):1555-1566.
    View in: PubMed
    Score: 0.055
  22. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021 10 01; 106(10):2667-2672.
    View in: PubMed
    Score: 0.052
  23. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021 06 10; 137(23):3272-3276.
    View in: PubMed
    Score: 0.051
  24. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.
    View in: PubMed
    Score: 0.051
  25. Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. Front Oncol. 2021; 11:648655.
    View in: PubMed
    Score: 0.051
  26. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
    View in: PubMed
    Score: 0.050
  27. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1414-1420.
    View in: PubMed
    Score: 0.050
  28. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021 01; 192(2):e38-e42.
    View in: PubMed
    Score: 0.049
  29. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935.
    View in: PubMed
    Score: 0.049
  30. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):3123-3127.
    View in: PubMed
    Score: 0.048
  31. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020 06; 95(6):623-629.
    View in: PubMed
    Score: 0.047
  32. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes? EJHaem. 2020 Jul; 1(1):272-276.
    View in: PubMed
    Score: 0.047
  33. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma. 2020 06; 61(6):1380-1387.
    View in: PubMed
    Score: 0.047
  34. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61.
    View in: PubMed
    Score: 0.042
  35. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646.
    View in: PubMed
    Score: 0.042
  36. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1146-1154.
    View in: PubMed
    Score: 0.040
  37. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8.
    View in: PubMed
    Score: 0.035
  38. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.034
  39. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):175-82.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.